second generation HPV E6 targeting TCR-based T-cell therapy (Kite Pharma/bluebird bio)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namesecond generation HPV E6 targeting TCR-based T-cell therapy (Kite Pharma/bluebird bio)
Drug Alias Nameanti-HPV-16 E6 TCR T-cell therapy (Kite Pharma/bluebird bio)
ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHuman leukocyte antigen modulatorsProtein E6 modulators
TargetsProtein E6Human leukocyte antigen
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKite Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenetix Biotherapeutics IncKite Pharma Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A